The use of high-sensitivity assays for C-reactive protein in clinical practice
Kiran Musunuru1, Brian G Kral, Roger S Blumenthal
1Johns Hopkins Ciccarone Preventive Cardiology Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. kmusunu1@jhmi.edu
Insights
High-sensitivity C-reactive protein (hs-CRP) testing aids cardiovascular disease (CVD) risk assessment in intermediate-risk individuals. Combining hs-CRP with LDL-cholesterol levels improves CVD risk stratification for targeted prevention strategies.
Area of Science:
- Biomarkers and Cardiovascular Health
- Preventive Cardiology
- Clinical Risk Assessment
Background:
- Cardiovascular disease (CVD) remains a leading cause of mortality globally.
- Accurate risk stratification is crucial for effective CVD prevention strategies.
- Traditional risk factors may not fully identify all individuals at elevated CVD risk.
Purpose of the Study:
- To evaluate the utility of high-sensitivity C-reactive protein (hs-CRP) assays in CVD risk assessment.
- To determine the role of hs-CRP testing in guiding preventive therapies for asymptomatic individuals.
- To assess the combined value of hs-CRP and LDL-cholesterol in CVD risk stratification.
Main Methods:
- Review of current evidence supporting the use of hs-CRP assays.
- Analysis of data on hs-CRP in relation to traditional CVD risk factors.
- Evaluation of hs-CRP in combination with LDL-cholesterol for risk stratification.
Main Results:
- High-sensitivity C-reactive protein assays accurately measure an important inflammatory biomarker.
- Evidence supports using hs-CRP testing in selected asymptomatic individuals at intermediate CVD risk.
- hs-CRP testing is recommended for those not already indicated for aspirin or statin therapy.
Conclusions:
- High-sensitivity C-reactive protein assays are valuable tools for CVD risk assessment.
- Combining hs-CRP with LDL-cholesterol measurements enhances risk stratification for selected patients.
- These assays assist in tailoring preventive strategies for cardiovascular disease.
Abstract:
High-sensitivity assays that accurately measure levels of the inflammatory biomarker C-reactive protein have been proposed for use in assessments of risk for cardiovascular disease (CVD). A growing body of evidence supports recommendations for these tests in selected asymptomatic individuals deemed to be at intermediate risk of CVD according to traditional risk-factor assessments and who do not already warrant chronic treatment with aspirin and statin therapy. Data suggests that these high-sensitivity assays should be used in combination with measurements of LDL-cholesterol levels to assist risk stratification of selected patients for prevention of CVD.
More Related Videos
11:03Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
06:50A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
Published on: May 29, 2020
